Biosyent Inc. (RX) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Biosyent Inc. C$19.24, price C$16.54, upside +16.3%, quality 83 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Biosyent Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range C$6.11 – C$17.49 · fair‑value band C$12.67 – C$29.52 · the C$16.54 price screens below the C$19.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Biosyent in your weekly email
Every Wednesday you see whether Biosyent is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
Show more
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
Stock analysis
Biosyent Inc. (RX) currently trades at C$16.54, while our model-based Fair Value estimate is C$19.24, implying the stock looks roughly 14.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of C$20.36 per share, and 12 of the 26 models we run sit above the C$16.54 price.
Bear case: the Dividend Discount group reads lowest at C$2.20, and 14 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: C$12.67 (bear) to C$29.52 (bull), the price of C$16.54 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 83/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Biosyent Inc. reported revenue of C$43.1M in FY2025 versus C$28.6M in FY2021, a compound +10.7%/yr. Reported net income was C$9.0M in FY2025, compounding +9.4%/yr from FY2021.
Key figures
Market cap C$186M (≈ $132M) · P/E ratio 21.2 · P/S ratio 4.44 · EPS (TTM) C$0.7800 · Dividend yield 1.2% · Net margin 20.9% · Return on equity 22.3% · Return on assets (EBIT) 20.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 16%, RX screens cheaper than that median.
Fair Value models
Bear C$12.67Fair Value C$19.24Bull C$29.52
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (C$0.4259 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+22.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
Start year 2020 (pandemic). Over 10 years: +10.8% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+23.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.0%
Dividend (yield on the price)1.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.21% vs 12%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 26%
2025 sits 51% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about +9.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score83 · Top 25%
Fair Value upside+16% · Above median
Profitability
Return on equity (TTM)22% · Top 25%
Return on assets14% · Top 25%
Net margin (TTM)20% · Top 25%
Operating margin (TTM)25% · Top 25%
Growth and dividend
Revenue growth27% · Top 25%
Dividend yield (TTM)1.2% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Biosyent Inc. Fair Value". https://www.fairvalue-calculator.com/stock/RX
Frequently asked questions
Is Biosyent Inc. (RX) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of C$19.24 versus a price of C$16.54, about +16% upside (undervalued).
What is the fair value of RX?
Our model-based fair value for Biosyent Inc. is C$19.24 (as of Sep 23, 2026), built from audited fundamentals. The current price: C$16.54.
What is the quality score of RX?
Biosyent Inc. has a Quality Score of 83/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biosyent Inc. (RX)?
Our model-based price target is the fair value of C$19.24 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario C$12.67, optimistic scenario C$29.52. It is a calculation from audited fundamentals, not an analyst target.
What is the Biosyent Inc. stock forecast for 2026?
Our models put fair value at C$19.24, about +16% upside versus a price of C$16.54 (undervalued). Cautious scenario C$12.67, optimistic scenario C$29.52. The calculation is refreshed regularly with new filings.
What is the revenue of Biosyent Inc. (RX)?
Biosyent Inc. reported trailing-twelve-month revenue of about C$46.0M (latest available figure, as of Sep 23, 2026).
Does Biosyent Inc. pay a dividend?
Biosyent Inc. currently shows a dividend yield of about 1.21% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Biosyent Inc. (RX)?
For today's price to be fair in a discounted-cash-flow model, Biosyent Inc. would have to grow free cash flow by +12.2 % per year for five years (discount rate 11.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.0 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of RX use?
Our models discount Biosyent Inc. at 11.4 %: a base by market capitalisation (micro), damped by beta 0.64, country premium for Canada. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Biosyent Inc. that is +12.2 % per year a year over ten years, using the same discount rate (11.4 %) and the same formula as our fair value.
How much growth has Biosyent Inc. (RX) delivered so far?
Over the past 5 years revenue at Biosyent Inc. grew +14.0 % a year. The price currently implies +12.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Biosyent Inc. (RX) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Biosyent Inc. (+12.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Biosyent Inc. (RX)?
The free-cash-flow yield on the price is 4.63 %: that much free cash flow Biosyent Inc. produces per unit of market value. When it exceeds the discount rate of our models (11.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Biosyent Inc. (RX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biosyent Inc. it is C$19.24 per share (as of Sep 23, 2026), against a price of C$16.54. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Biosyent Inc. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, RX trades below its calculated fair value: price C$16.54, fair value C$19.24, a gap of about +16% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RX?
No. The price is what the market pays today (C$16.54); the fair value is what the company's own numbers justify (C$19.24). For Biosyent Inc. the two are C$2.70 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biosyent Inc. worth?
The market values Biosyent Inc. at about C$186M (market capitalisation, as of Sep 23, 2026). Per share that is C$16.54; our models calculate a fair value of C$19.24 per share.
What do the bullish and bearish scenarios say about RX?
Our models span a range for Biosyent Inc.: cautious scenario C$12.67, base C$19.24, optimistic C$29.52 per share (as of Sep 23, 2026, price C$16.54). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RX?
Biosyent Inc. trades at a price-to-earnings ratio of 21.2 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$19.24 is built from several models across several years. Other multiples: P/B 3.2, P/S 2.9, EV/EBITDA 8.8.
How solid is the balance sheet of Biosyent Inc. (RX)?
Balance-sheet figures for Biosyent Inc. (as of Sep 23, 2026): return on equity 22.3%. They feed the Quality Score of 83/100, which measures business quality independently of the share price.
How far is RX from its 52-week high?
Biosyent Inc. trades at C$16.54, about 5% below its 52-week high of C$17.49 and 56% above the low of C$10.58 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of C$19.24 is for.
Which stocks are comparable to Biosyent Inc.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biosyent Inc. stock attractive at the current price?
The data as of Sep 23, 2026: price C$16.54, calculated fair value C$19.24 (+16%), Quality Score 83/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RX calculated?
We run Biosyent Inc. through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of C$19.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Biosyent Inc. currently trades 16 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biosyent Inc. (RX)?
The closing price on Sep 23, 2026 was C$16.54. Our model-based fair value is C$19.24, about +16% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biosyent Inc. right now?
A fairly wide model range (C$12.67 to C$29.52) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Biosyent Inc. (RX) come from?
Earnings per share at Biosyent Inc. grew +13.5 % a year from 2012 to 2023. Broken into its drivers: revenue per share +16.7 %, EBIT margin −2.5 %, tax rate −0.9 %, residual (interest, one-offs) +0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Biosyent Inc.
How large is the market capitalisation of Biosyent Inc. (RX)?
The market capitalisation of Biosyent Inc. is C$186M (≈ $132M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biosyent Inc. (RX)?
The price-to-sales ratio of Biosyent Inc. is 4.44 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biosyent Inc. (RX)?
Earnings per share at Biosyent Inc. are C$0.7800 (price ÷ EPS = P/E 21.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Biosyent Inc. (RX)?
The dividend yield of Biosyent Inc. is 1.2% (payout 25.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Biosyent Inc. (RX)?
The net margin of Biosyent Inc. is 20.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biosyent Inc. (RX)?
The return on equity (ROE) of Biosyent Inc. is 22.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biosyent Inc. (RX)?
On an EBIT basis the return on assets of Biosyent Inc. is 20.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biosyent Inc. (RX)?
The operating margin of Biosyent Inc. is 24.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biosyent Inc. (RX)?
Revenue at Biosyent Inc. is growing +26.7% versus a year earlier (3y avg +15.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biosyent Inc. (RX)?
Earnings per share at Biosyent Inc. are growing +0.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Biosyent Inc. (RX) hold?
Biosyent Inc. holds more cash than debt, C$3.7M net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Biosyent Inc. in the live analysis
One click puts Biosyent Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
